Regeneron spent $5 billion repurchasing shares from Sanofi in May 2020 and $900 million repurchasing global rights to Libtayo in July 2022, yet a windfall from sales of its Covid antibody cocktail as ...

The results are very encouraging news for Amgen and Repatha, which is in a head-to-head marketing battle with Sanofi and Regeneron’s Praluent to be the dominant PCSK9 inhibitor. Both drugs have ...

Analysts had predicted that the new drug class would be priced at around $10,000 a year, so the premium being sought by Amgen and Sanofi in the US will increase calls for measures to pare down the ...

Sanofi SNY announced that the FDA has approved the label expansion ... The SNY drug is also approved in combination with Amgen’s Kyprolis (carfilzomib) and dexamethasone for treating patients with ...

A newly described stage of a lymph node-like structure seen in liver tumors after presurgical immunotherapy may be vital to ...

Patients with advanced bladder cancer that had spread to other parts of the body (metastasised) have responded well in a ...

An interim analysis from a long-term open-label extension study has underlined the clinical efficacy and safety of ...

Tracking patient response to DMARD therapy has the potential to improve remission, but multiple barriers must be overcome ...

New data released by Merck suggests AstraZeneca and Sanofi’s Beyfortus, the monoclonal antibody injection that protects ...

Sanofi is now in “exclusive negotiations” with U.S. private equity firm Clayton, Dubilier & Rice (CD&R) to sell a 50% controlling stake in its consumer health business Opella. With the French ...

Sanofi is aiming to sign an agreement this weekend to sell control of its consumer health business to Clayton Dubilier & Rice, following a last-ditch attempt by a rival bidder to derail the deal ...

French pharmaceutical company Sanofi confirmed on Monday its plans to sell a controlling stake in its consumer health unit Opella to a US investment fund, after providing the French government ...